FIGURE 4.

Response profile of 30 patients treated with anti‐BCMA CAR T cells. (A) Response distribution in the 30 patients. Ninety percent of them were responders, including 56.7% showing ≥VGPR. (B) Left: C _max of transgenic vector copy level between responder and non‐responders; Right: Comparison of Cmax between patients with achieved ≥VGPR and DOR > median (148 days) and other responders (≤PR and DOR ≤148 days). Responders had significantly higher C _max than non‐responders, and there was a trend that deep responders were having higher C _max